TrialAdvances in therapy2023

Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial.

November McGarvey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.